Astrocyte Pharmaceuticals raised $9.5 million in Series B financing to advance Phase 2 development of its AST-004 brain injury therapy.
- Amount
- $9.5M
- Stage
- Series B
- Announced
- 30 September 2026
- Lead
- DeepWork Capital
- Other investors
- MintPharma Capital, Waterstar Capital, Dynagrow Capital, Angel Star Ventures
- Use of funds
- Advance continued Phase 2 development of AST-004, including completing the STARFAST trial.
- Total raised
- $40M to date
- Checked
- Announced by the company